Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Clinical Training: Hands-on experience in patient care under supervision. Research: Residents are required to undertake research projects, culminating in a dissertation. Teaching: Involvement in the education of medical students and junior colleagues. Continuous Assessment: Regular evaluations through examinations, logbooks, and performance appraisals.
In 1988, Bio-Synthesis helped in the synthesis and characterization of a new class of peptides with novel antimicrobial properties discovered at the NIH. In 1989, OCS became incorporated as Bio-synthesis, Inc. and moved its laboratories to Lewisville, Texas. In 1993, Bio-Synthesis was one of the first peptide synthesis companies to acquire a Finnigan MALDI-TOF mass spectrometer for the accurate quality control of synthetic peptides produced in-house. In 1994, Bio-synthesis pioneered the use of molecular methods for HLA analysis which is applied in organ matching for transplantation purposes. Later in the same year Bio-Synthesis held the first major HLA DNA typing workshop with the attendance of HLA laboratory directors from around the country in conjunction with University of North Texas in Denton Texas.
Speer, William (1870). The oldest and the newest empire: China and the United States. Hartford, Conn., S. S. Scranton and company; Philadelphia, Parmelee & co.; [etc., etc.] Thelwall, A. S. (1839). The iniquities of the opium trade with China; being a development of the main causes which exclude the merchants of Great Britain from the advantages of an unrestricted commercial intercourse with that vast empire. With extracts from authentic documents. London : Wm. H. Allen and Co. Turner, Frederick Storrs (1876). British opium policy and its results to India and China. London, S. Low, Marston, Searle, & Rivington. Matthee RP (2005). The Pursuit of Pleasure: Drugs and Stimulants in Iranian History, 1500–1900. Princeton, New Jersey: Princeton University Press. ISBN 978-0691118550.
Sources: en.wikipedia.org
== Culture == In July 1977, a New York Times article describing new plastic surgery techniques which could partially correct the appearance of those with Treacher Collins syndrome was widely circulated resulting in raised awareness of the disease. Prior to beginning his comedy career, Bob Saget made a documentary short called "Through Adam's Eyes" documenting his young nephew's experiences undergoing facial reconstructive surgery due to Treacher Collins; the film won a Student Academy Award. The disorder was featured on the show Nip/Tuck, in the episode "Blu Mondae". TLC's Born Without a Face features Juliana Wetmore, who was born with the most severe case in medical history of this syndrome and is missing 30%–40% of the bones in her face. In 2010, BBC Three documentary Love Me, Love My Face covered the case of a man, Jono Lancaster, with the condition. In 2011, BBC Three returned to Jono to cover his and his partner Laura's quest to start a family, in So What If My Baby Is Born Like Me?, which first aired as part of a BBC Three season of programmes on parenting. The first film was replayed on BBC One shortly ahead of the second film's initial BBC Three broadcast. Lancaster's third BBC Three film, Finding My Family on Facebook, which looked at adoption, aired in 2011. Lancaster's memoir about living with the condition, Not All Heroes Wear Capes, published in 2023. In Wonder, a children's novel written by R. J. Palacio, the main character is a child who has Treacher Collins syndrome.
=== Depression === A 2016 Cochrane review concluded that for major depressive disorder, "Given the absence of high quality evidence and the inability to draw firm conclusions based on that evidence, the use of SAMe for the treatment of depression in adults should be investigated further.". A 2020 systematic review found that it performed significantly better than placebo, and had similar outcomes to other commonly used antidepressants (imipramine and escitalopram).
The United States occupied Iraq between the toppling of the Ba'athist Iraqi government and the dissolution of the Coalition Provisional Authority on 28 June 2004. Thereafter, the United States remained in Iraq after obtaining United Nations Security Council approvals and resolutions, negotiated with involvement from the Transitional Government of Iraq. On 1 January 2009, the Government of Iraq obtained full responsibility for security in all of Iraq. Consequently, United States Forces – Iraq did not have responsibility for, nor control of, any ground in Iraq. Its mission was limited to defense and security cooperation only.
=== Iodothyronine deiodinase === Central to human (and vertebrate in general) thyroid hormone metabolism are three iodothyronine deiodinases, with gene symbols DIO1, DIO2, DIO3 in humans. Related proteins have been found in invertebrate chordates, mostly with a selenocystine, though a few have cystine instead.
Sources: en.wikipedia.org
=== Use by non-military groups === Terrorist groups have used C-4 worldwide in acts of terrorism and insurgency, as well as domestic terrorism and state terrorism. On May 13, 1985, the Philadelphia Police Department dropped a C-4 bomb on the home of the MOVE organization, killing eleven people — including five children — and wiping out 61 homes in two city blocks in a subsequent fire. Composition C-4 is recommended in al-Qaeda's traditional curriculum of explosives training. In October 2000, the group used C-4 to attack the USS Cole, killing 17 sailors. In 1996, Saudi Hezbollah terrorists used C-4 to blow up the Khobar Towers, a U.S. military housing complex in Saudi Arabia. Composition C-4 has also been used in improvised explosive devices by Iraqi insurgents.
=== Mechanism of action === Posaconazole works by disrupting the functions of certain fungal and protozoal membrane-bound enzyme systems. It does this by blocking the synthesis and turnover of the eukaryotic cell membrane component ergosterol via the inhibition of an enzyme known as CYP51. Posaconazole is significantly more potent at binding to CYP51 than itraconazole.
The new honey is then placed in honeycomb cells, which are left uncapped. This honey still has a very high water content, up to 70%, depending on the concentration of nectar gathered. At this stage of its refinement the water content of the honey is high enough that ubiquitous yeast spores can reproduce in it, a process which, if left unchecked, would rapidly consume the new honey's sugars. To combat this, bees use an ability rare among insects: the endogenous generation of heat. Bees are among the few insects that can create large amounts of body heat. They use this ability to produce a constant ambient temperature in their hives. Hive temperatures are usually around 35 °C (95 °F) in the honey-storage areas. This temperature is regulated either by generating heat with their bodies or removing it through water evaporation. The evaporation removes water from the stored honey, drawing heat from the colony. The bees use their wings to govern hive cooling. Coordinated wing beating moves air across the wet honey, drawing out water and heat. Ventilation of the hive eventually expels both excess water and heat into the outside world. The process of evaporating continues until the honey reaches its final water content of between 15.5% and 18%. This concentrates the sugars far beyond the saturation point of water, which is to say there is far more sugar dissolved in what little water remains in honey than ever could be dissolved in an equivalent volume of water. Honey, even at hive temperatures, is therefore a supercooled solution of various sugars in water.
=== Greek philosophy === In Ancient Greece, Aristotle remarked on the importance of semen: "For Aristotle, semen is the residue derived from nourishment, that is of blood, that has been highly concocted to the optimum temperature and substance. This can only be emitted by the male as only the male, by nature of his very being, has the requisite heat to concoct blood into semen." According to Aristotle, there is a direct connection between food and semen: "Sperms are the excretion of our food, or to put it more clearly, as the most perfect component of our food." The connection between food and physical growth, on the one hand, and semen, on the other, allows Aristotle to warn against "engag[ing] in sexual activity at too early an age ... [since] this will affect the growth of their bodies. Nourishment that would otherwise make the body grow is diverted to the production of semen.
== Theoretical models == All materials are made of atoms, which are dipoles. These dipoles modify light velocity by a factor n (the refractive index). In a split ring resonator the ring and wire units act as atomic dipoles: the wire acts as a ferroelectric atom, while the ring acts as an inductor L, while the open section acts as a capacitor C. The ring as a whole acts as an LC circuit. When the electromagnetic field passes through the ring, an induced current is created. The generated field is perpendicular to the light's magnetic field. The magnetic resonance results in a negative permeability; the refraction index is negative as well. (The lens is not truly flat, since the structure's capacitance imposes a slope for the electric induction.) Several (mathematical) material models predict frequency response in DNGs. One of these is the Lorentz model, which describes electron motion in terms of a driven-damped, harmonic oscillator. The Debye relaxation model applies when the acceleration component of the Lorentz mathematical model is small compared to the other components of the equation. The Drude model applies when the restoring force component is negligible and the coupling coefficient is generally the plasma frequency. Other component distinctions call for the use of one of these models, depending on its polarity or purpose. Three-dimensional composites of metal/non-metallic inclusions periodically/randomly embedded in a low permittivity matrix are usually modeled by analytical methods, including mixing formulas and scattering-matrix based methods.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.